EE200000039A - MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine - Google Patents

MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine

Info

Publication number
EE200000039A
EE200000039A EEP200000039A EEP200000039A EE200000039A EE 200000039 A EE200000039 A EE 200000039A EE P200000039 A EEP200000039 A EE P200000039A EE P200000039 A EEP200000039 A EE P200000039A EE 200000039 A EE200000039 A EE 200000039A
Authority
EE
Estonia
Prior art keywords
tumor cells
transfected
ligand
mhc class
cells
Prior art date
Application number
EEP200000039A
Other languages
English (en)
Estonian (et)
Inventor
Triebel Frdric
Original Assignee
Institut Gustave Roussy
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy, Applied Research Systems Ars Holding N.V. filed Critical Institut Gustave Roussy
Publication of EE200000039A publication Critical patent/EE200000039A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000039A 1997-07-25 1998-07-23 MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine EE200000039A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (fr) 1997-07-25 1997-07-25 Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
PCT/EP1998/004621 WO1999004810A2 (fr) 1997-07-25 1998-07-23 Utilisation de ligands cmh de classe ii comme adjuvants pour la vaccination et utilisation de lag-3 dans le traitement du cancer

Publications (1)

Publication Number Publication Date
EE200000039A true EE200000039A (et) 2000-10-16

Family

ID=8229825

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000039A EE200000039A (et) 1997-07-25 1998-07-23 MHC II klassi ligandi kasutamine, farmatseutiline kompositsioon, transfekteeritud kasvajarakud, transfekteeritud rakkude ja kasvajarakkude valmistamismeetod ning nende kasutamine

Country Status (19)

Country Link
US (2) US6410509B1 (fr)
EP (3) EP0893507A1 (fr)
JP (1) JP4723722B2 (fr)
KR (1) KR100603075B1 (fr)
CN (1) CN1184320C (fr)
AT (2) ATE478956T1 (fr)
AU (1) AU753738B2 (fr)
BR (1) BR9811037A (fr)
CA (2) CA2732570C (fr)
DE (2) DE69841866D1 (fr)
DK (1) DK1002108T3 (fr)
EA (3) EA003740B1 (fr)
EE (1) EE200000039A (fr)
ES (1) ES2262242T3 (fr)
IL (2) IL134212A0 (fr)
NO (1) NO20000378L (fr)
PT (1) PT1002108E (fr)
UA (1) UA75322C2 (fr)
WO (1) WO1999004810A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (fr) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides et proteines se liant aux motifs glu-pro, compositions thérapeutiques les comprenant et leurs applications
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (fr) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
EP2044949A1 (fr) * 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2011031139A1 (fr) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. Protéine ataq ou fragment de celle-ci pouvant être utilisé en tant que vaccin
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
JP5986576B2 (ja) 2010-11-10 2016-09-06 ラボラトリオス レティ，エセ．エレ． 新規アジュバント
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2935423C (fr) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Molecules d'anticorps anti-pd-1 et leurs utilisations
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
WO2015138920A1 (fr) 2014-03-14 2015-09-17 Novartis Ag Molécules d'anticorps anti-lag-3 et leurs utilisations
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (fr) * 2015-04-07 2021-03-31 Cytlimic Inc. Médicament comprenant un agoniste au recepteur toll like 3 et une proteine lag-3
EP3294324A1 (fr) 2015-05-13 2018-03-21 Agenus Inc. Vaccins pour le traitement et la prévention du cancer
EP3744340A3 (fr) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions et procédés pour le traitement du cancer
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (fr) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Inuline à longue chaîne pour stimuler une réponse immunitaire
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US20230057310A1 (en) * 2018-09-27 2023-02-23 Genocea Biosciences, Inc. Treatment methods
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1990001870A1 (fr) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Vecteurs de retrovirus exprimant des cd4 solubles: therapie genique pour le sida
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1994016737A1 (fr) * 1993-01-26 1994-08-04 Weiner David B Compositions et procedes d'administration de matieres genetiques
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
CA2194488A1 (fr) * 1994-08-05 1996-02-15 Tod Paul Holler Procede d'utilisation d'une integrase retrovirale negative transdominante dans le traitement d'infection retrovirale
PL320610A1 (en) * 1994-12-07 1997-10-13 Hoffmann La Roche Fragments of monoclonal antibodies of immunosuppressive activity
JPH10511652A (ja) * 1994-12-23 1998-11-10 ラボラトワール・オン・ソシエテ・アノニム 炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.

Also Published As

Publication number Publication date
EA005405B1 (ru) 2005-02-24
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (fr) 1999-01-27
KR20010021706A (ko) 2001-03-15
KR100603075B1 (ko) 2006-07-20
WO1999004810A2 (fr) 1999-02-04
JP4723722B2 (ja) 2011-07-13
EA003740B1 (ru) 2003-08-28
DE69834330D1 (de) 2006-06-01
ATE478956T1 (de) 2010-09-15
DK1002108T3 (da) 2006-08-21
CA2293805A1 (fr) 1999-02-04
WO1999004810A3 (fr) 1999-07-08
EP1002108A2 (fr) 2000-05-24
EP1698701A1 (fr) 2006-09-06
IL134212A (en) 2012-03-29
EP1002108B1 (fr) 2006-04-26
US6410509B1 (en) 2002-06-25
CA2732570C (fr) 2014-11-18
ATE324455T1 (de) 2006-05-15
AU9254798A (en) 1999-02-16
CN1265149A (zh) 2000-08-30
BR9811037A (pt) 2000-08-01
PT1002108E (pt) 2006-09-29
EP1698701B1 (fr) 2010-08-25
EA200300092A1 (ru) 2003-06-26
UA75322C2 (en) 2006-04-17
HK1030014A1 (en) 2001-04-20
DE69841866D1 (de) 2010-10-07
CN1184320C (zh) 2005-01-12
NO20000378D0 (no) 2000-01-25
IL134212A0 (en) 2001-04-30
EA200200565A1 (ru) 2002-10-31
AU753738B2 (en) 2002-10-24
US20020192195A1 (en) 2002-12-19
NO20000378L (no) 2000-01-25
JP2001510806A (ja) 2001-08-07
CA2732570A1 (fr) 1999-02-04
CA2293805C (fr) 2011-05-03
DE69834330T2 (de) 2007-03-29
ES2262242T3 (es) 2006-11-16
US7109026B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
PT1002108E (pt) Utilizacao de ligandos de mhc classe ii como adjuvantes para vacinacao e de lag-3 no tratamento de cancro
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
GB2063671B (en) Composition for the treatment of keratin fibred based on amphoteric polymers and cationic polymers
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
ATE145132T1 (de) Therapeutische zusammensetzung und verfahren für ihre herstellung
ATE433959T1 (de) Analoge von kokain
DK96588A (da) Antitumirmiddel indeholdende makromolekylaere platinforbindelser
DE68905000D1 (de) Zusammensetzung fuer die behandlung von fasern.
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE109973T1 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
DE69828191D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin
EP1037918A4 (fr) Procede et composition pour ameliorer l'efficacite d'un vaccin
DE59010838D1 (de) Glycosyl-Etoposid-Prodrugs, Verfahren zu ihrer Herstellung und ihre Anwendung in Kombination mit funktionalisierten tumorspezifischen Enzym-Konjugaten
ES491340A0 (es) Procedimiento para la obtencion de 11-alquilen-morfantridi- nas 6-sustituidas
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
FI900372A7 (fi) Aryyli- ja heteroaryylietanoli-pyridyylialkyyliamiinit, menetelmä niiden valmistamiseksi ja niiden käyttö suoritusta edistävinä aineina eläimillä ja liikalihavuuden hoitoon käytettävinä aineina
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
DE3863136D1 (de) Derivate des 2,2-bis-(3-aminophenyl)-hexafluorpropans und verfahren zur herstellung des 2,2-bis-(3,4-diaminophenyl)-hexafluorpropans.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
FI834429A7 (fi) 3',5'-diarabinosidien valmistus ja terapeuttinen soveltaminen.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
IT7822143V0 (it) Ancoraggio per trefoli e simili, particolarmente per l'impiego nel consolidamento di edifici lesionati.
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner